Posted by Michael Wonder on 25 Sep 2017
Gilead receives approval in Canada for expanded indication of Epclusa (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C in patients co-infected with HIV
21 September 2017 - New data for first approved pan-genotypic once-daily single tablet regimen for chronic hepatitis C virus infection.
Gilead Sciences Canada today announced that Health Canada has granted a Notice of Compliance (NOC) for updated labelling of Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regime for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV-1.
Health Canada granted Epclusa an NOC in July 2016, for the treatment of adults with genotype 1-6 chronic HCV infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis in combination with ribavirin.
